SQZ raises $16M in series B

SQZ Biotechnologies Co. (Boston, Mass.) raised $16 million in a series B round led by NanoDimension and Polaris Partners. Undisclosed new and existing investors also participated.

SQZ's CellSqueeze microfluidic-based system constrains cells to force open transient pores in the cell membrane and allows delivery of bioactive materials into the cells. CEO Armon Sharei told BioCentury the company hopes to use its protein delivery system to engineer antigen presentation mechanisms for immuno-oncology applications (see BioCentury Innovations, Nov. 3, 2014). ...